Parallax Volatility Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Parallax Volatility Advisers’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,200	Closed	-$63K	–	4003
2019 Q1	$63K	Buy	+10,200	New	+$49.3K	﹤0.01%	2223
2018 Q4	–	Sell	-6,082	Closed	-$40K	–	4225
2018 Q3	$40K	Buy	+6,082	New	+$45.2K	﹤0.01%	1949
2018 Q1	–	Sell	-2,184	Closed	-$28K	–	4683
2017 Q4	$28K	Buy	+2,184	New	+$32.1K	﹤0.01%	3536

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parallax Volatility Advisers's JNCE Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2019, closing a stake of 10,200 shares — an estimated $63K sold.

Parallax Volatility Advisers first reported a position in JNCE in Q4 2017 and held it in 3 quarters. The position peaked at $63K in Q1 2019. 80 funds tracked by Wall St. Rank hold JNCE as of Q2 2019.

Parallax Volatility Advisers reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Parallax Volatility Advisers sold 10,200 Jounce Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $63K.
Parallax Volatility Advisers first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
Parallax Volatility Advisers's Jounce Therapeutics, Inc. Common Stock position peaked at $63K in Q1 2019.
80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.